18.05.2018 13:10:29

DGAP-News: HAEMATO AG - IFRS Results Q1 2018

DGAP-News: HAEMATO AG / Key word(s): Quarterly / Interim Statement/Quarter Results
HAEMATO AG - IFRS Results Q1 2018

18.05.2018 / 13:10
The issuer is solely responsible for the content of this announcement.

HAEMATO AG - IFRS Results Q1 2018  

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the company started its own development of innovative medical products for the beauty market. HAEMATO AG assumes that the first products will come onto the market next year, which has already created the basis for further growth and additional earnings.

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.8 million (previous year: EUR 68.0 million) and an operating result (EBIT) of EUR 4.0 million in the first quarter of 2018. Sales increased by 2.8% compared to the same period of the previous year. The Executive Board is optimistic that it will achieve the targets set for the 2018 financial year.


HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of business activities is on the growth markets of high-priced special pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the HAEMATO AG share:
Subscribed capital: EUR 21,980,000
Listed class of share: Bearer shares
ISIN: DE0006190705 * WKN: 619070 * Ticker symbol: HAE

HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70

18.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Lilienthalstraße 5c
12529 Schönefeld
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.de
Internet: www.haemato.de
ISIN: DE0006190705
WKN: 619070
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange

End of News DGAP News Service

687669  18.05.2018 


Analysen zu HAEMATO AGmehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!

Aktien in diesem Artikel